Tg Therapeutics, Inc.
Clinical trials sponsored by Tg Therapeutics, Inc., explained in plain language.
-
MS patients may soon get a shot instead of an IV drip
Disease control OngoingThis phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety…
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Ublituximab shows promise for Long-Term MS control in large extension trial
Disease control OngoingThis study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC